{"id":3977,"date":"2015-04-22T09:55:00","date_gmt":"2015-04-22T09:55:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&#038;p=3977"},"modified":"2022-04-04T15:33:30","modified_gmt":"2022-04-04T15:33:30","slug":"advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/de\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/","title":{"rendered":"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis."},"content":{"rendered":"<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Hashiguchi+K&amp;cauthor_id=25823500\">Keiichi Hashiguchi<\/a><sup>&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25823500\/#affiliation-1\">1<\/a><\/sup>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Takeshima+F&amp;cauthor_id=25823500\">Fuminao Takeshima<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Akazawa+Y&amp;cauthor_id=25823500\">Yuko Akazawa<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Matsushima+K&amp;cauthor_id=25823500\">Kayoko Matsushima<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Minami+H&amp;cauthor_id=25823500\">Hitomi Minami<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Machida+H&amp;cauthor_id=25823500\">Haruhisa Machida<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Yamaguchi+N&amp;cauthor_id=25823500\">Naoyuki Yamaguchi<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Shiozawa+K&amp;cauthor_id=25823500\">Ken Shiozawa<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ohba+K&amp;cauthor_id=25823500\">Kazuo Ohba<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ohnita+K&amp;cauthor_id=25823500\">Ken Ohnita<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Ichikawa+T&amp;cauthor_id=25823500\">Tatsuki Ichikawa<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Isomoto+H&amp;cauthor_id=25823500\">Hajime Isomoto<\/a>,&nbsp;<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/?term=Nakao+K&amp;cauthor_id=25823500\">Kazuhiko Nakao<\/a>, Digestion. 2015;91(3):208-17.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><strong>Background:\u00a0<\/strong>Fecal lactoferrin has been introduced as a useful tool for the diagnosis and monitoring of inflammatory bowel disease (IBD). The aim of this study was to assess if fecal lactoferrin can be employed to predict or estimate the effect of granulocyte and monocyte adsorptive apheresis (GMA) in ulcerative colitis (UC). <strong>Methods:\u00a0<\/strong>This was a prospective study involving 21 patients with UC. Patients with moderately-to-severely active UC who were scheduled to undergo GMA were recruited. Changes in fecal lactoferrin concentration were compared between the GMA-responder and -nonresponder groups. <strong>Results:\u00a0<\/strong>In the GMA-responder group, fecal lactoferrin significantly increased 1 week after the introduction of GMA and then significantly decreased after GMA sessions. Fecal lactoferrin concentrations were significantly higher in the GMA-responder group than in the GMA-nonresponder group at 1 and 2 weeks after the introduction of GMA. Multivariate logistic regression analysis revealed that fecal lactoferrin concentration 1 week after the introduction of GMA was the most contributing factor for the effectiveness of GMA in patients with UC. <strong>Conclusions:\u00a0<\/strong>In the GMA-responder group, fecal lactoferrin concentration significantly increased 1 week after the introduction of GMA. Fecal lactoferrin may be beneficial for predicting clinical response of GMA in patients with UC at an early stage of GMA treatment.<\/p>\n<\/div>\n\n<div class=\"post-content max-w-987 mx-auto px-20 lg:px-0\">\n<p><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25823500\/\">https:\/\/pubmed.ncbi.nlm.nih.gov\/25823500\/<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Keiichi Hashiguchi&nbsp;1,&nbsp;Fuminao Takeshima,&nbsp;Yuko Akazawa,&nbsp;Kayoko Matsushima,&nbsp;Hitomi Minami,&nbsp;Haruhisa Machida,&nbsp;Naoyuki Yamaguchi,&nbsp;Ken Shiozawa,&nbsp;Kazuo Ohba,&nbsp;Ken Ohnita,&nbsp;Tatsuki Ichikawa,&nbsp;Hajime Isomoto,&nbsp;Kazuhiko Nakao, Digestion. 2015;91(3):208-17. Background:\u00a0Fecal lactoferrin has been introduced as a useful tool for the diagnosis and monitoring of inflammatory bowel disease (IBD). The aim of this study was to assess if fecal lactoferrin can be employed to predict or estimate the effect [&hellip;]<\/p>\n","protected":false},"template":"","scientific_tags":[144,147,614,152,312,315],"class_list":["post-3977","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-biomarker","scientific_tags-clinical-remission","scientific_tags-effectiviness","scientific_tags-fecal-lactoferrin","scientific_tags-immunology","scientific_tags-others"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte\" \/>\n<meta property=\"og:description\" content=\"Keiichi Hashiguchi&nbsp;1,&nbsp;Fuminao Takeshima,&nbsp;Yuko Akazawa,&nbsp;Kayoko Matsushima,&nbsp;Hitomi Minami,&nbsp;Haruhisa Machida,&nbsp;Naoyuki Yamaguchi,&nbsp;Ken Shiozawa,&nbsp;Kazuo Ohba,&nbsp;Ken Ohnita,&nbsp;Tatsuki Ichikawa,&nbsp;Hajime Isomoto,&nbsp;Kazuhiko Nakao, Digestion. 2015;91(3):208-17. Background:\u00a0Fecal lactoferrin has been introduced as a useful tool for the diagnosis and monitoring of inflammatory bowel disease (IBD). The aim of this study was to assess if fecal lactoferrin can be employed to predict or estimate the effect [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2022-04-04T15:33:30+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data1\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/\",\"name\":\"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2015-04-22T09:55:00+00:00\",\"dateModified\":\"2022-04-04T15:33:30+00:00\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/","og_locale":"de_DE","og_type":"article","og_title":"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte","og_description":"Keiichi Hashiguchi&nbsp;1,&nbsp;Fuminao Takeshima,&nbsp;Yuko Akazawa,&nbsp;Kayoko Matsushima,&nbsp;Hitomi Minami,&nbsp;Haruhisa Machida,&nbsp;Naoyuki Yamaguchi,&nbsp;Ken Shiozawa,&nbsp;Kazuo Ohba,&nbsp;Ken Ohnita,&nbsp;Tatsuki Ichikawa,&nbsp;Hajime Isomoto,&nbsp;Kazuhiko Nakao, Digestion. 2015;91(3):208-17. Background:\u00a0Fecal lactoferrin has been introduced as a useful tool for the diagnosis and monitoring of inflammatory bowel disease (IBD). The aim of this study was to assess if fecal lactoferrin can be employed to predict or estimate the effect [&hellip;]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/","og_site_name":"Adacyte","article_modified_time":"2022-04-04T15:33:30+00:00","twitter_card":"summary_large_image","twitter_misc":{"Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/","name":"Advantages of Fecal Lactoferrin Measurement during Granulocyte and Monocyte Adsorptive Apheresis Therapy in Ulcerative Colitis. - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2015-04-22T09:55:00+00:00","dateModified":"2022-04-04T15:33:30+00:00","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/advantages-of-fecal-lactoferrin-measurement-during-granulocyte-and-monocyte-adsorptive-apheresis-therapy-in-ulcerative-colitis\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner\/3977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/media?parent=3977"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/de\/wp-json\/wp\/v2\/scientific_tags?post=3977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}